Yahoo · Oct 5, 2026
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North America and Europe -- -- PM577 granted Rare Pediatric Disease Designation by the U.S. FDA -- -- Initial clinical data expected in 2027 -- CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME),
